FibromyalgiaNCT06103058
The Prevalence of Fibromyalgia in Adults at Al-Karak Jordan a Cross-sectional Study
An observational study of Fibromyalgia and Orthopedic Disorder, run by Mutah University at 1 site in Jordan.
Trial summary
Fibromyalgia is a chronic and intricate musculoskeletal disorder characterized by widespread pain, fatigue, and tenderness in specific anatomical regions. Although its prevalence varies among populations, understanding the prevalence in different geographical areas is crucial for healthcare planning. Read more about this study
- Who is it for?
- Ages 1 month to 100 yearsHealthy volunteers can take part
- Conditions the study is for
- Fibromyalgia, Orthopedic Disorder
- What is being tested?
- Cross sectional
- How many people
- 965 participants
- Where
- 1 siteJordan
- Study dates
- 12 May 2023to 31 Dec 2024
- How long will I take part?
- 6 Months
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 1 month to 100 years
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Study population: The study found a 26.5% prevalence of fibromyalgia in the studied population. Female gender, mental health illnesses, and comorbidities like irritable bowel syndrome, psychiatric disorders, and rheumatological and neurological diseases were significantly associated with fibromyalgia. Age, BMI, marital status, employment status, and certain comorbidities did not show statistically significant predictive value. Discussion: The significant prevalence of fibromyalgia and its links to female gender, mental health problems, and comorbidities highlight the necessity for specific healthcare interventions and public awareness initiatives. The study's findings help to understand the imp
Using google forms, this cross-sectional study was carried out, and the participants were reached via social media platforms (5)
. Participants' autonomy was maintained, and no direct benefit was gained in return for filling out the questionnaire. The ethics committee at the Faculty of Medicine, Mutah University, Karak, Jordan, provided the required ethical approval prior to the initiation of this study. Moreover, the committee ensured that the study was designed according to the principles of the Declaration of Helsinki (Date: 13 February 2023. Reference number: 992023). In this study, the authors targeted Karak government citizens, in Jordan. Accordingly, the required sample size to achieve a 99% Confidence interval was 663 participants.
Trial locations and contacts
1 site in 1 country.
Jordan1 site, 1 recruiting
- Recruiting
Mutah University
Qīr Moāv, 61710
Mutah University, 0796383747, mabujeyyab@yahoo.com
About this study
Fibromyalgia is a chronic and intricate musculoskeletal disorder characterized by widespread pain, fatigue, and tenderness in specific anatomical regions. Although its prevalence varies among populations, understanding the prevalence in different geographical areas is crucial for healthcare planning. This cross-sectional study aims to determine the prevalence of fibromyalgia in adults residing in Al-Karak, Jordan. The city's unique demographic and environmental characteristics may influence the occurrence of fibromyalgia among its adult population. The study aims to address gaps in knowledge, provide localized insights, and shed light on fibromyalgia's burden on the community's health. Accurate prevalence data aids healthcare planning and resource allocation.
- Conditions
- Fibromyalgia, Orthopedic Disorder
- Being tested
- Cross sectional
- Medical subject headings
- Fibromyalgia, Musculoskeletal Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Cross sectionalOther
Cross sectional
| Study group | Role | What they receive |
|---|---|---|
| Positive for fibromyalgia | 26.5% prevalence of fibromyalgia | |
| Negative for fibromyalgia | 26.5% prevalence of fibromyalgia Receives: Other: Cross sectional |
What is being measured
The primary outcome is the main question the study is designed to answer.
Cross sectional
Outcome measurements
Measured: 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Oct 2023
- Study start12 May 2023
- Primary completion31 Dec 2024 (estimated)
- Study completion31 Dec 2024 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for FibromyalgiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Cross-sectional
- Enrolment
- 965 participants (estimated)
- Target duration
- 6 Months
Sponsor and investigators
- Lead sponsor
- Mutah University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mohammad Abu-Jeyyab, Mutah University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06103058
- Sponsor's protocol ID
- 20235012
- Status last verified
- Oct 2023
- First submitted
- 22 Oct 2023
- Last updated
- 26 Oct 2023
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 26 Oct 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Prevalence of Fibromyalgia in Adults at Al-Karak Jordan a Cross-sectional Study
- ClinicalTrials.gov ID
- NCT06103058
- Acronym / sponsor ID
- 20235012
- Conditions
- Fibromyalgia, Orthopedic Disorder
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 965 participants (estimated)
- Lead sponsor
- Mutah UniversityUniversity, hospital or other
- Study start
- 12 May 2023 (actual)
- Primary completion
- 31 Dec 2024 (estimated)
- Study completion
- 31 Dec 2024 (estimated)
- First posted
- 26 Oct 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Fibromyalgia is a chronic and intricate musculoskeletal disorder characterized by widespread pain, fatigue, and tenderness in specific anatomical regions. Although its prevalence varies among populations, understanding the prevalence in different geographical areas is crucial for healthcare planning. This cross-sectional study aims to determine the prevalence of fibromyalgia in adults residing in Al-Karak, Jordan. The city's unique demographic and environmental characteristics may influence the occurrence of fibromyalgia among its adult population. The study aims to address gaps in knowledge, provide localized insights, and shed light on fibromyalgia's burden on the community's health. Accurate prevalence data aids healthcare planning and resource allocation.
Study design
- Observational model
- Other
- Time perspective
- Cross-sectional
- Target follow-up
- 6 Months
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Positive for fibromyalgia | – | –26.5% prevalence of fibromyalgia |
| Negative for fibromyalgia | – | Other: Cross sectional26.5% prevalence of fibromyalgia |
Who may qualify
- Ages
- 1 month to 100 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
- Study population
- The study found a 26.5% prevalence of fibromyalgia in the studied population. Female gender, mental health illnesses, and comorbidities like irritable bowel syndrome, psychiatric disorders, and rheumatological and neurological diseases were significantly associated with fibromyalgia. Age, BMI, marital status, employment status, and certain comorbidities did not show statistically significant predictive value. Discussion: The significant prevalence of fibromyalgia and its links to female gender, mental health problems, and comorbidities highlight the necessity for specific healthcare interventions and public awareness initiatives. The study's findings help to understand the imp
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Cross sectionalCross sectional | Other | Negative for fibromyalgia |
Primary outcome
Cross sectional
Time frame: 2 years
Outcome measurements
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Oct 2023.
- Individual participant dataSharing planned: Undecided
Related trials for Fibromyalgia
Active, not recruiting
Objective Measurement of Pain Regulation in Individuals Who Have Received Internet-delivered Exposure-based Cognitive Behavior Therapy
Fibromyalgia
Enrolling by invitationPhase 3
Open-Label Safety Study of AXS-14 in Subjects With Fibromyalgia
Fibromyalgia
Recruiting
Exercise Interventions and Dietary Advice in Fibromyalgia and IBS
Fibromyalgia, Irritable Bowel Syndrome
Recruiting
Whole-body Cryotherapy in Those With Chronic Fatigue: A Feasibility Study
ME/CFS, Fibromyalgia (FM)
Recruiting
Auricular Acupuncture for Autonomic Balance and Pain in Fibromyalgia
Fibromyalgia Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Fibromyalgia and Orthopedic Disorder, run by Mutah University at 1 site in Jordan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 26 Oct 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Jordan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Mohammad Abu-Jeyyab, MD (+962796383747, mabujeyyab@yahoo.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Cross sectional (time frame: 2 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Oct 2023.